NCT03052062View on ClinicalTrials.gov

Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

July 3, 2018

Study Completion Date

July 3, 2018

Conditions
Obese
Interventions
DIETARY_SUPPLEMENT

Lipidrive

LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day

Trial Locations (1)

63000

Centre d'Investigation Clinique, Clermont-Ferrand

All Listed Sponsors
collaborator

University Hospital, Clermont-Ferrand

OTHER

collaborator

Université Blaise Pascal, Clermont-Ferrand

OTHER

collaborator

Biofortis Mérieux NutriSciences

OTHER

lead

Valbiotis

INDUSTRY

NCT03052062 - Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03) | Biotech Hunter | Biotech Hunter